Listen Now
Topics Covered
- Overview of HER2-Positive Metastatic Breast Cancer, in the Context of COVID-19
- Biomarker, Genomic & Diagnostic Testing: Grade and Hormone Receptors
- Standard Treatment Options, including Targeted Therapy
- How Biomarker Testing Informs Treatment Decisions
- New & Emerging Targeted Treatments
- Updates on Investigational New Drugs in Clinical Trials
- How Research Contributes to Your Treatment Options
- What’s New in the Prevention & Management of Treatment Side Effects, Discomfort & Long-Term Effects
- The Increasing Role of Telemedicine/Telehealth Appointments
- Guidelines to Prepare for Telemedicine/ Telehealth Appointments, including Technology, List of Questions & OpenNotes Discussion
- Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns
- Questions for Our Panel of Experts
Our Panel of Experts

Generosa Grana, MD, FACP
Medical Director, MD Anderson Cancer Center at Cooper, The Cooper Health System, Professor of Medicine, Cooper Medical School at Rowan University

Minetta C. Liu, MD
Professor and Research Chair, Division of Medical Oncology, Department of Oncology, Consultant, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Medical Director, Office of Specialty Collaborations and Contracts, Co-Leader, Genomics in Action Strategic Priority, Center for Individualized Medicine, Mayo Clinic

Sara A. Hurvitz, MD, FACP
Professor of Medicine, Director, Breast Cancer Clinical Trials Program, Division of Hematology-Oncology, David Geffen School of Medicine, UCLA, Medical Director, Clinical Research Unit, Jonsson Comprehensive Cancer Center

Jennifer M. Matro, MD
Associate Clinical Professor of Medicine, Division of Hematology/Oncology, University of California San Diego Health

Lauren Chatalian, MSW
Women & Children’s Program Manager, CancerCare
Brochure
You can download the brochure for this workshop
Workshop Date
This workshop was originally recorded on October 13, 2021.